M. Martín-Mateos

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

J. Miguel, A. Oriol, N. Gutiérrez, 2010, The Lancet. Oncology.

followed by maintenance myeloma patients receiving short induction with weekly bortezomib Outcome according to cytogenetic abnormalities and DNA ploidy in

J. Miguel, A. Oriol, N. Gutiérrez, 2012 .

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.

A. Oriol, N. Gutiérrez, B. Paiva, 2011, Blood.

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

A. Oriol, B. Paiva, J. Bargay, 2014, Blood.

Next Generation Sequencing for Diagnosis of Hereditary Anemia: Experience in a Spanish Reference Center.

M. Morado, Eduardo Salido-Fiérrez, E. Cela, 2022, Clinica chimica acta; international journal of clinical chemistry.

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

A. Oriol, N. Gutiérrez, J. Bargay, 2012, Blood.